Tivozanib (AV-951), 血管内皮生长因子受体抑制剂

VEGFR1 Selective Inhibitors
有货

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
T409225-1ml
1ml 现货 Stock Image
查看相关系列
Compound libraries (12332)

基本描述

别名 替沃扎尼(AV-951)
英文别名 KRN-951 | 1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea
规格或纯度 Moligand™, 10mM in DMSO
英文名称 Tivozanib (AV-951)
生化机理 Tivozanib(AV-951,KRN-951)是一种强效的选择性血管内皮生长因子受体(VEGFR)抑制剂,对 VEGFR1/2/3 的 IC50 为 30 nM/6.5 nM/15 nM,还能抑制 PDGFR 和 c-Kit,对 FGFR-1、Flt3、c-Met、EGFR 和 IGF-1R 的活性较低。第 3 阶段
储存温度 -80℃储存
运输条件 超低温冰袋运输
作用类型 抑制剂
作用机制 血管内皮生长因子受体抑制剂
产品介绍

Tivozanib (AV-951)是VEGFR抑制剂,对VEGFR1,2和3的IC50分别为30 nM,6.5 nM和15 nM,还能抑制PDGFR和c-Kit,对FGFR-1,Flt3,c-Met,EGFR和IGF-1R的抑制性较低。

Information

Tivozanib (AV-951, KRN-951) is a potent and selectiveVEGFRinhibitor forVEGFR1/2/3with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.
In vitro

AV-951 is a novel quinoline-urea derivative. AV-951 blocks VEGF-dependent activation of mitogen-activated protein kinases and proliferation of endothelial cells.

In vivo

In vivo studies show that AV-951 also decreases the micro vessel density and suppresses VEGFR2 phosphorylation levels in tumor xenografts, especially at a concentration of 1mg/kg (p.o. administration). AV-951 shows almost complete inhibition of tumor xenografts growth (TGI>85%) in athymic rats. Another study in rat peritoneal disseminated tumor model shows that AV-951 could prolong the survival of the tumor-bearing rats with the MST of 53.5 days. AV-951 displays antitumor activity against many human tumor xenografts including lung, breast, colon, ovarian, pancreas and prostate cancer.
Cell Data

cell lines:

Concentrations:1 μM

Incubation Time:15 minutes

Powder Purity:≥95%

产品属性

IC50 VEGFR1, IC50: 30 nM

关联靶点(人)

RET Tclin 原癌基因酪氨酸蛋白激酶受体 Ret(Proto-oncogene tyrosine-protein kinase receptor Ret) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
FLT4 Tclin 血管内皮生长因子受体 3(Vascular endothelial growth factor receptor 3) (3 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
EPHB2 Tchem 肝素 B 型受体 2(Ephrin type-B receptor 2) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
PEBP1 Tchem 磷脂酰乙醇胺结合蛋白 1(Phosphatidylethanolamine-binding protein 1) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
PDGFRA Tclin 血小板衍生生长因子受体α(Platelet-derived growth factor receptor alpha) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
BCR Tclin 断点簇区域蛋白质(Breakpoint cluster region protein) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
FLT1 Tclin 血管内皮生长因子受体 1(Vascular endothelial growth factor receptor 1) (3 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
KDR Tclin 血管内皮生长因子受体 2(Vascular endothelial growth factor receptor 2) (4 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

名称和识别符

分子类型 小分子
Canonical SMILES COC1=CC2=C(C=C1OC)C(=CC=N2)OC3=CC=C(NC(=O)NC4=NOC(=C4)C)C(=C3)Cl
分子量 454.86

化学和物理性质

溶解性 Solubility (25°C) In vitro DMSO: 50 mg/mL (198.23 mM); Water: 17 mg/mL (67.4 mM); Ethanol: Insoluble;

安全和危险性(GHS)

技术规格说明书

Concentration(Compounding value) 9.0-11.0(mmol/L)
Proton NMR spectrum Conforms to Structure
Record the entire process by video Conform

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

溶液计算器

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.